A novel property of hexokinase inhibition by Favipiravir and proposed advantages over Molnupiravir and 2 Deoxy D glucose in treating COVID-19.

Published in: Biotechnology letters (2022)

Favipiravir could continue to be part of the COVID-19 treatment regimen due to its resistance to host esterases, hexokinase inhibition potential and proven safety through human trials.

Keyphrases

coronavirus disease
sars cov
endothelial cells
induced pluripotent stem cells
respiratory syndrome coronavirus
blood glucose
metabolic syndrome
blood pressure
adipose tissue
combination therapy
risk assessment